

Summary of minutes of EUCAST Steering Committee Meeting Brussels, Belgium, 8-9 February 2010

Attending

Dr Derek F.J. Brown	DB	Scientific Secretary	United Kingdom
Dr Rafael Cantón	RC	Clinical Data Co-ordinator	Spain
Prof Claude-James Soussy	CS	CA-SFM	France
Dr Christian Giske	CG	SRGA	Sweden
Dr Antti Hakanen	AH	EUCAST	Finland
Prof Gunnar Kahlmeter	GK	Chairperson	Sweden
Prof Alasdair P. MacGowan	AM	BSAC	United Kingdom
Dr Johan W. Mouton	JM	CRG	The Netherlands
Prof Arne Rodloff	AR	DIN	Germany
Dr Martin Steinbakk	MS	NWGA	Norway
Prof Paul Tulkens	PT	EUCAST	Belgium
Present on 8 February			
Prof Luc Dubrueil	LD	CA-SFM	France
Dr Johan van Eldere	JV	NAC Chairman	Belgium

1	Chairman's welcome GK welcomed JV.
2	Minutes of meeting of 23-24 November 2009 The minutes were accepted as a correct record.
3	<p>Matters arising from minutes of 23-24 November 2009 A paper for CMI explaining ECOFFs is to be prepared.</p> <p>MIC data on anaerobes and <i>H. pylori</i> are being collected. MICs and ECOFFs will be added to the wild type database.</p> <p>A note on intrinsic resistance in some clostridia has been sent to the expert rules subcommittee.</p> <p>Proposals on breakpoints and expert rules for ESBLs and carbapenemases were sent on wide distribution for comment.</p> <p>A table of changes in the new version of the expert rules is to be prepared. A paper for CMI is being prepared and a revised computer program is to be assessed.</p> <p>Amendments to the diffusion method description and slideshow, and organism-based breakpoint tables have been completed and they were released on the EUCAST website in December 2009.</p>
4	New drugs A cephalosporin and a new formulation of a peptide agent are in the EMEA process.
5	Status of EUCAST documents It was agreed to add the EUCAST logo and a foreword to each document. The status of documents was reviewed and several are close to completion.
6	Breakpoints and expert rules for ESBLs Responses to the general consultation on the recent proposals suggest that the I/R breakpoint is too high if results were to be reported as found. A further proposal will be sent for general consultation.
7	Expert rules subcommittee Once there is a decision on cephalosporin breakpoints for Enterobacteriaceae and reporting of ESBL producers, the revised version of the expert rules document will be finalised.
8	Antifungal susceptibility testing subcommittee There will be a joint meeting with the Steering Committee at ECCMID in April 2010.
9	Anaerobe subcommittee A study of test methodology has been started.
10	Organisms without EUCAST breakpoints <i>Helicobacter</i> spp., <i>C. difficile</i> , <i>Campylobacter</i> spp., <i>Legionella</i> spp., <i>Listeria</i> spp. and <i>Pasteurella multocida</i> are being investigated.

11	Breakpoints for mupirocin A proposal for breakpoints will be sent to national committees.
12	Breakpoints for colistin It was agreed to go to wide consultation with breakpoints of 4/4 mg/L for <i>P. aeruginosa</i> .
13	ESCMID/ECCMID The ECCMID Vienna workshop will be 09.30-12.30 on Saturday 10 th April. The ECCMID Vienna General Committee Meeting will be 15.30-16.30 on Saturday 10 th April. The ESCMID Educational Workshop on susceptibility testing will be in Madrid 27-30 th September
14	CLSI GK and RC attended the CLSI meeting in January and summarised the main points. The carbapenem breakpoints proposed last June were confirmed (imipenem, meropenem, doripenem 1/2 mg/L, ertapenem 0.25/0.5 mg/L).
15	ECDC No new information.
16	EMA Guidance for industry on the data needed for registration of new antibacterial drugs is being prepared and EUCAST will be consulted in the near future.
17	Implementation of EUCAST breakpoints The status of commercial systems regarding EUCAST breakpoints was reviewed. Automated systems are at various stages of readiness. Breakpoint tables combining MIC and disk diffusion breakpoints have been published. An early update will be needed to include minor corrections and links to additional rationale documents. An online version of breakpoint tables will be included in clinical breakpoint and disk diffusion sections on the EUCAST website. The latest version of Acrobat is needed to use the links in the pdf breakpoint table. EUCAST MIC-zone diameter correlates are based on MICs and zone diameters for collections of organisms with MIC/zone close to breakpoints, existing MIC v zone diameter data, and specific studies of target organisms and target resistance mechanisms. The disk diffusion slideshow has been translated to German and a French version will be prepared.
18	New glycopeptide An update on progress of recent studies was presented by the company.
19	Agents without breakpoints Mupirocin, polymyxinB, bacitracin, sulfadiazine and neomycin are topical agents and breakpoints are likely to be based on ECOFFs. Sulfonamides, nalidixic acid, streptomycin, spiramycin and cefradine will be assessed.
20	EUCAST in Belgium JV gave a presentation on experience with introducing EUCAST breakpoints in Belgium.
21	New glycopeptide 2 Proposed breakpoints were reassessed in the light of new data.
22	Any other business CRG will be replaced by a group called SWAB.
23	Next meetings
23.1	13-14 April 2010, Vienna, Austria (after ECCMID). 5-6 July 2010, Stockholm, Sweden. 26-27 September 2010, Madrid, Spain. 22-23 November 2010, Basel, Switzerland. 14-15 February 2011, to be decided. 10-11 May 2011, Milan, Italy (after ECCMID). 11-12 July 2011, Stockholm, Sweden. 5-6 September 2011, Munich, Germany.

Ratified summary of minutes of meeting 8-9 February 2010. Prepared by DB, GK and RC